A study in the Pan02 model of mouse pancreatic cancer revealed that the combination of agnostic anti-OX40 and inhibitory anti-CTLA4 led to transient decrease in ARG1 expression in TAMs, giving a therapeutic window for gemcitabine (346). Here, CTLA4 is linked to familial pancreatic carcinoma.